Your browser doesn't support javascript.
loading
Core Outcome Set for IgE-mediated food allergy clinical trials and observational studies of interventions: International Delphi consensus study 'COMFA'.
Demidova, Anastasia; Drewitz, Karl Philipp; Kimkool, Parisut; Banjanin, Nikolina; Barzylovich, Vladyslava; Botjes, Erna; Capper, India; Castor, Mary Anne R; Comberiati, Pasquale; Cook, Emma E; Costa, Joana; Chu, Derek K; Epstein, Michelle M; Galvin, Audrey Dunn; Giovannini, Mattia; Girard, Frédéric; Golding, Michael A; Greenhawt, Matthew; Ierodiakonou, Despo; Jones, Christina J; Khaleva, Ekaterina; Knibb, Rebecca C; Macit-Çelebi, Melahat Sedanur; Mack, Douglas P; Mafra, Isabel; Marchisotto, Mary Jane; Mijakoski, Dragan; Nekliudov, Nikita; Özdemir, Cevdet; Patel, Nandinee; Pazukhina, Ekaterina; Protudjer, Jennifer L P; Rodríguez Del Rio, Pablo; Roomet, Jelena; Sammut, Patrick; Schoos, Ann-Marie Malby; Schopfer, Anita Fossaluzza; Schultz, Fallon; Seylanova, Nina; Skypala, Isabel; Sørensen, Martin; Stoleski, Sasho; Stylianou, Eva; Upton, Julia; van de Veen, Willem; Genuneit, Jon; Boyle, Robert J; Apfelbacher, Christian; Munblit, Daniel.
Afiliación
  • Demidova A; Independent Researcher, Limassol, Cyprus.
  • Drewitz KP; Institute of Social Medicine and Health Systems Research, Medical Faculty, Otto von Guericke University, Magdeburg, Germany.
  • Kimkool P; Department of Pediatric Allergy, Imperial College Healthcare NHS Trust, London, UK.
  • Banjanin N; Institute of Hygiene and Medical Ecology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Barzylovich V; Department of Pediatrics, National Medical University named after O.O. Bogomolets, Kyiv, Ukraine.
  • Botjes E; Dutch Food Allergy SVA, Nijkerk, The Netherlands.
  • Capper I; University of Nottingham, Nottingham, UK.
  • Castor MAR; Division of Allergy and Immunology, Department of Pediatrics, College of Medicine-Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
  • Comberiati P; Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.
  • Cook EE; Modern Japanese Studies Program, Graduate School of Media and Communication, Hokkaido University, Sapporo, Japan.
  • Costa J; REQUIMTE-LAQV, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.
  • Chu DK; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Epstein MM; Experimental Allergy Laboratory, Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Galvin AD; School of Applied Psychology, University College Cork, Cork, Ireland.
  • Giovannini M; Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Girard F; Department of Health Sciences, University of Florence, Florence, Italy.
  • Golding MA; DBV Technologies, Montrouge, France.
  • Greenhawt M; The Children's Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Ierodiakonou D; Department of Pediatrics, Section of Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Jones CJ; Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.
  • Khaleva E; School of Psychology, University of Surrey, Guildford, UK.
  • Knibb RC; Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Macit-Çelebi MS; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Mack DP; School of Psychology, Aston Institute of Health and Neurodevelopment, Aston University, Birmingham, UK.
  • Mafra I; Department of Nutrition and Dietetics, Faculty of Health Sciences, Ondokuz Mayis University, Samsun, Turkey.
  • Marchisotto MJ; Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
  • Mijakoski D; REQUIMTE-LAQV, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.
  • Nekliudov N; MJM Advisory, LLC, New York, New York, USA.
  • Özdemir C; Department for Allergic Diseases, Institute of Occupational Health of R.N. Macedonia, WHO Collaborating Center, Skopje, North Macedonia.
  • Patel N; Department of Occupational Medicine, Faculty of Medicine, Ss. Cyril and Methodius, University in Skopje, Skopje, North Macedonia.
  • Pazukhina E; Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
  • Protudjer JLP; Department of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Turkey.
  • Rodríguez Del Rio P; Department of Pediatric Allergy, Imperial College Healthcare NHS Trust, London, UK.
  • Roomet J; Heybeliada, Istanbul, Turkey.
  • Sammut P; The Children's Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Schoos AM; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Schopfer AF; Allergy department, Hospital Universitario Infantil Niño Jesus, Madrid, Spain.
  • Schultz F; Centre for Allergology and Immunology, East Tallinn Central Hospital, Tallinn, Estonia.
  • Seylanova N; Department of Paediatrics, Mater Dei Hospital, Msida, Malta.
  • Skypala I; COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital-Herlev and Gentofte, Gentofte, Denmark.
  • Sørensen M; Department of Pediatrics, Slagelse Sygehus, Slagelse, Denmark.
  • Stoleski S; Allergissima Association, Crissier, Switzerland.
  • Stylianou E; International FPIES Association (IFPIES), Point Pleasant Beach, New Jersey, USA.
  • Upton J; Independent Researcher, London, UK.
  • van de Veen W; Department of Inflammation and Repair, Imperial College London, London, UK.
  • Genuneit J; Regional center for asthma, allergy and hypersensitivity, University Hospital of North Norway, Tromsø, Norway.
  • Boyle RJ; Department for Allergic Diseases, Institute of Occupational Health of R.N. Macedonia, WHO Collaborating Center, Skopje, North Macedonia.
  • Apfelbacher C; Department of Occupational Medicine, Faculty of Medicine, Ss. Cyril and Methodius, University in Skopje, Skopje, North Macedonia.
  • Munblit D; Department of Pulmonary Medicine, Regional Centre for Asthma, Allergy and Hypersensitivity, Oslo University Hospital, Oslo, Norway.
Allergy ; 79(4): 977-989, 2024 04.
Article en En | MEDLINE | ID: mdl-38433402
ABSTRACT

BACKGROUND:

IgE-mediated food allergy (FA) is a global health concern with substantial individual and societal implications. While diverse intervention strategies have been researched, inconsistencies in reported outcomes limit evaluations of FA treatments. To streamline evaluations and promote consistent reporting, the Core Outcome Measures for Food Allergy (COMFA) initiative aimed to establish a Core Outcome Set (COS) for FA clinical trials and observational studies of interventions.

METHODS:

The project involved a review of published clinical trials, trial protocols and qualitative literature. Outcomes found as a result of review were categorized and classified, informing a two-round online-modified Delphi process followed by hybrid consensus meeting to finalize the COS.

RESULTS:

The literature review, taxonomy mapping and iterative discussions with diverse COMFA group yielded an initial list of 39 outcomes. The iterative online and in-person meetings reduced the list to 13 outcomes for voting in the formal Delphi process. One more outcome was added based on participant suggestions after the first Delphi round. A total of 778 participants from 52 countries participated, with 442 participating in both Delphi rounds. No outcome met a priori criteria for inclusion, and one was excluded as a result of the Delphi. Thirteen outcomes were brought to the hybrid consensus meeting as a result of Delphi and two outcomes, 'allergic symptoms' and 'quality of life' achieved consensus for inclusion as 'core' outcomes.

CONCLUSION:

In addition to the mandatory reporting of adverse events for FA clinical trials or observational studies of interventions, allergic symptoms and quality of life should be measured as core outcomes. Future work by COMFA will define how best to measure these core outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Hipersensibilidad a los Alimentos Límite: Humans Idioma: En Revista: Allergy Año: 2024 Tipo del documento: Article País de afiliación: Chipre

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Hipersensibilidad a los Alimentos Límite: Humans Idioma: En Revista: Allergy Año: 2024 Tipo del documento: Article País de afiliación: Chipre